Two engineered AAV vectors, self‐complementary (sc) AAV vectors encoding murine αPD‐1 in the scFv‐Fc format (HER2‐AAV‐IgG‐Fc) and single‐stranded (ss) AAV vectors encoding the full‐length antibody nivolumab (HER2‐AAV‐αPD‐1), lead to efficient tumor cells transduction, functional aPD‐1 secretion and subsequent T cells reactivation without affecting target antigen expression, which could be applied in straight‐forward tumor‐targeted ICI delivery in combination with chemo‐ or radiotherapy [141, 142]. Here, ERBB2 is linked to neoplasm.